{
  "doc_id": "rak-watrobowokomorkowy-podsumowanie-zalecen",
  "created_date": "unknown_year",
  "country": "PO",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "cancer cancer (with with cirrhosis) diameter diameter < of of ≤ 4 months (per per year). carcinoma carcinoma (wash-in or wash-out) lesion lesion (table 3) control control (approximately 3 months), regarding regarding patient'material material (non-cellular). evaluation evaluation (postoperative postoperative material). the the patient'cancer cancer (intra-hepatic carcinomas) approximately approximately 70% of of pre- points points (a), (b) and (c). thermoablation thermoablation (A A microwave) of of > methods methods (arterial chemoembolization + I, a thermoablation) levels levels ≥ 400 ng/athesolizumab athesolizumab (or or cabozanib).",
      "start_page": 1,
      "end_page": 6
    },
    {
      "heading": "heading heading <none>",
      "text": "Row 1: Recommendation* Row 2: prophylaxis prophylaxis • Row 3: Row Row 5: steatosis. steatosis.II; A Row 6: Row Row 9: gene. gene.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "heading heading <none>",
      "text": "Rov 1: Row Row 2: of of < years years (3 3 months).Row Row 3: of of > examination examination (dynamic dynamic MRI). Row Row 10: tumours tumours ≥ evaluation. evaluation.",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "heading heading <none>",
      "text": "Rov 1: lesions lesions > magnetic magnetic resonance; changes changes > based based on: (1) phase phase (wash-in) and (2) phase phase (was-out) hepatocellular hepatocellular carcinoma; met met (wash-in or wash-out), lesion lesion (tab. 3) control control (approximately 3 months), Row Row 12: therapy. therapy.II/Row Row 13: conduct conduct (treatment treatment regimen) Row 14: row row 15: system system (figure 2) tumor. tumor.",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "heading heading <none>",
      "text": "Row Row 3: are are recommended- II II , B row 4: the the patient's liver 5: Row Row 13: Row Row 14: criteria criteria (3 3 cm) exceed exceed 3% one-year one-year one- 10%.row row 15: tests. tests.II; A Row 16: methods methods (ablatory) months months (bridge is transplantation).",
      "start_page": 4,
      "end_page": 4
    },
    {
      "heading": "heading heading <none>",
      "text": "Row 1: criteria. criteria. • Row 2: waiting waiting period; Row Row 14: transplantation transplantation (bridge therapy) treatment treatment (advanced advanced stage).Row Row 15: chemoembolization chemoembolization / Radiodembolization Row 16: treatment treatment (first first line) B. B.",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <none> (column 2)",
      "text": "Row 1: Row 2: III, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <none> (column 2)",
      "text": "Row 1: Row Row 2: row row 3: Row Row 4: Row Row 5: III, Arow 6: Row Row 7: Row Row 8: Raw Raw 9: row row 10: II, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <none> (column 2)",
      "text": "Row 1: Row Row 2: Row Row 3: Row Row 4: I, B",
      "start_page": 5,
      "end_page": 5
    },
    {
      "heading": "heading heading <none>",
      "text": "Rov 1: Rov Rov 2: Row Row 3: Row Row 4: Row Row 5: Pugha Pugha ≤ B7, with infiltration/vein vein (renal renal tract), AFP AFP ≥ 400 ng/Row Row 16: athezolizumab athezolizumab (or or cabozantinib).Row Row 17: Row Row 18: used. used.",
      "start_page": 6,
      "end_page": 6
    }
  ]
}